|
1
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herrero R, Castellsagué X, Pawlita M,
Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B,
Pintos J, et al IARC Multicenter Oral Cancer Study Group: Human
papillomavirus and oral cancer: The International Agency for
Research on Cancer multicenter study. J Natl Cancer Inst.
95:1772–1783. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xiao H and Yang CS: Combination regimen
with statins and NSAIDs: A promising strategy for cancer
chemoprevention. Int J Cancer. 123:983–990. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Prasanna P, Thibault A, Liu L and Samid D:
Lipid metabolism as a target for brain cancer therapy: Synergistic
activity of lovastatin and sodium phenylacetate against human
glioma cells. J Neurochem. 66:710–716. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xia Z, Tan MM, Wong WW, Dimitroulakos J,
Minden MD and Penn LZ: Blocking protein geranylgeranylation is
essential for lovastatin-induced apoptosis of human acute myeloid
leukemia cells. Leukemia. 15:1398–1407. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhuang L, Kim J, Adam RM, Solomon KR and
Freeman MR: Cholesterol targeting alters lipid raft composition and
cell survival in prostate cancer cells and xenografts. J Clin
Invest. 115:959–968. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Blais L, Desgagné A and LeLorier J:
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the
risk of cancer: A nested case-control study. Arch Intern Med.
160:2363–2368. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Graaf MR, Beiderbeck AB, Egberts AC,
Richel DJ and Guchelaar HJ: The risk of cancer in users of statins.
J Clin Oncol. 22:2388–2394. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Friis S, Poulsen AH, Johnsen SP,
McLaughlin JK, Fryzek JP, Dalton SO, Sørensen HT and Olsen JH:
Cancer risk among statin users: A population-based cohort study.
Int J Cancer. 114:643–647. 2005. View Article : Google Scholar
|
|
11
|
Olsen JH, Johansen C, Sørensen HT,
McLaughlin JK, Mellemkjaer L, Steffensen FH and Fraumeni JF Jr:
Lipid-lowering medication and risk of cancer. J Clin Epidemiol.
52:167–169. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kaye JA and Jick H: Statin use and cancer
risk in the General Practice research Database. Br J Cancer.
90:635–637. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Poynter JN, Gruber SB, Higgins PD, Almog
R, Bonner JD, Rennert HS, Low M, Greenson JK and Rennert G: Statins
and the risk of colorectal cancer. N Engl J Med. 352:2184–2192.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Khurana V, Bejjanki HR, Caldito G and
Owens MW: Statins reduce the risk of lung cancer in humans: A large
case-control study of US veterans. Chest. 131:1282–1288. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Farwell WR, Scranton RE, Lawler EV, Lew
RA, Brophy MT, Fiore LD and Gaziano JM: The association between
statins and cancer incidence in a veterans population. J Natl
Cancer Inst. 100:134–139. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Khurana V, Caldito G and Ankem M: Statins
might reduce risk of renal cell carcinoma in humans: Case-control
study of 500,000 veterans. Urology. 71:118–122. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kulp SK, Yang YT, Hung CC, Chen KF, Lai
JP, Tseng PH, Fowble JW, Ward PJ and Chen CS:
3-phosphoinositide-dependent protein kinase-1/Akt signaling
represents a major cyclooxygenase-2-independent target for
celecoxib in prostate cancer cells. Cancer Res. 64:1444–1451. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Johnson AJ, Hsu AL, Lin HP, Song X and
Chen CS: The cyclooxygenase-2 inhibitor celecoxib perturbs
intracellular calcium by inhibiting endoplasmic reticulum
Ca2+-ATPases: A plausible link with its anti-tumour
effect and cardiovascular risks. Biochem J. 366:831–837. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luciani MG, Campregher C and Gasche C:
Aspirin blocks proliferation in colon cells by inducing a G1 arrest
and apoptosis through activation of the checkpoint kinase ATM.
Carcinogenesis. 28:2207–2217. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thun MJ, Henley SJ and Patrono C:
Nonsteroidal anti-inflammatory drugs as anticancer agents:
Mechanistic, pharmacologic, and clinical issues. J Natl Cancer
Inst. 94:252–266. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Giardiello FM, Hamilton SR, Krush AJ,
Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR and
Offerhaus GJ: Treatment of colonic and rectal adenomas with
sulindac in familial adenomatous polyposis. N Engl J Med.
328:1313–1316. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Labayle D, Fischer D, Vielh P, Drouhin F,
Pariente A, Bories C, Duhamel O, Trousset M and Attali P: Sulindac
causes regression of rectal polyps in familial adenomatous
polyposis. Gastroenterology. 101:635–639. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nugent KP, Farmer KC, Spigelman AD,
Williams CB and Phillips RK: Randomized controlled trial of the
effect of sulindac on duodenal and rectal polyposis and cell
proliferation in patients with familial adenomatous polyposis. Br J
Surg. 80:1618–1619. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Steinbach G, Lynch PM, Phillips RK,
Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y,
Fujimura T, et al: The effect of celecoxib, a cyclooxygenase-2
inhibitor, in familial adenomatous polyposis. N Engl J Med.
342:1946–1952. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bertagnolli MM, Eagle CJ, Zauber AG,
Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J,
Corle D, et al APC Study Investigators: Celecoxib for the
prevention of sporadic colorectal adenomas. N Engl J Med.
355:873–884. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arber N, Eagle CJ, Spicak J, Rácz I, Dite
P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, et al PreSAP
Trial Investigators: Celecoxib for the prevention of colorectal
adenomatous polyps. N Engl J Med. 355:885–895. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bresalier RS, Sandler RS, Quan H,
Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D,
Lanas A, et al Adenomatous Polyp Prevention on Vioxx (APPROVe)
Trial Investigators: Cardiovascular events associated with
rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J
Med. 352:1092–1102. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kerr DJ, Dunn JA, Langman MJ, Smith JL,
Midgley RS, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, et
al VICTOR Trial Group: Rofecoxib and cardiovascular adverse events
in adjuvant treatment of colorectal cancer. N Engl J Med.
357:360–369. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Solomon SD, McMurray JJ, Pfeffer MA,
Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E and
Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study
Investigators: Cardiovascular risk associated with celecoxib in a
clinical trial for colorectal adenoma prevention. N Engl J Med.
352:1071–1080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Swamy MV, Cooma I, Reddy BS and Rao CV:
Lamin B, caspase-3 activity, and apoptosis induction by a
combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: A
novel approach in developing effective chemopreventive regimens.
Int J Oncol. 20:753–759. 2002.PubMed/NCBI
|
|
31
|
Agarwal B, Rao CV, Bhendwal S, Ramey WR,
Shirin H, Reddy BS and Holt PR: Lovastatin augments
sulindac-induced apoptosis in colon cancer cells and potentiates
chemopreventive effects of sulindac. Gastroenterology. 117:838–847.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zheng X, Cui XX, Avila GE, Huang MT, Liu
Y, Patel J, Kong AN, Paulino R, Shih WJ, Lin Y, et al: Atorvastatin
and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.
Clin Cancer Res. 13:5480–5487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hoffmeister M, Chang-Claude J and Brenner
H: Individual and joint use of statins and low-dose aspirin and
risk of colorectal cancer: A population-based case-control study.
Int J Cancer. 121:1325–1330. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Flick ED, Habel LA, Chan KA, Van Den Eeden
SK, Quinn VP, Haque R, Orav EJ, Seeger JD, Sadler MC, Quesenberry
CP Jr, et al: Statin use and risk of prostate cancer in the
California Men's Health Study cohort. Cancer Epidemiol Biomarkers
Prev. 16:2218–2225. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Taga T, Hibi M, Hirata Y, Yamasaki K,
Yasukawa K, Matsuda T, Hirano T and Kishimoto T: Interleukin-6
triggers the association of its receptor with a possible signal
transducer, gp130. Cell. 58:573–581. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
He G, Dhar D, Nakagawa H, Font-Burgada J,
Ogata H, Jiang Y, Shalapour S, Seki E, Yost SE, Jepsen K, et al:
Identification of liver cancer progenitors whose malignant
progression depends on autocrine IL-6 signaling. Cell. 155:384–396.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Trikha M, Corringham R, Klein B and Rossi
JF: Targeted anti-interleukin-6 monoclonal antibody therapy for
cancer: a review of the rationale and clinical evidence. Clin
Cancer Res. 9:4653–4665. 2003.PubMed/NCBI
|
|
38
|
Zhang GJ and Adachi I: Serum interleukin-6
levels correlate to tumor progression and prognosis in metastatic
breast carcinoma. Anticancer res. 19:1427–1432. 1999.PubMed/NCBI
|
|
39
|
Zabaleta J, Su LJ, Lin HY, Sierra RA, Hall
MC, Sartor AO, Clark PE, Hu JJ and Ochoa AC: Cytokine genetic
polymorphisms and prostate cancer aggressiveness. Carcinogenesis.
30:1358–1362. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li A, Varney ML and Singh RK: Expression
of interleukin 8 and its receptors in human colon carcinoma cells
with different metastatic potentials. Clin Cancer res. 7:3298–3304.
2001.PubMed/NCBI
|
|
41
|
Ren Y, Poon RT, Tsui HT, Chen WH, Li Z,
Lau C, Yu WC and Fan ST: Interleukin-8 serum levels in patients
with hepatocellular carcinoma: correlations with
clinicopathological features and prognosis. Clin Cancer res.
9:5996–6001. 2003.PubMed/NCBI
|
|
42
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chan GG, Tai BC, Liang S, Lim DT and Soo
KC: Squamous cell carcinoma of the head and neck (HNSCC) -
multi-modality treatment and impact on survival. Asian J Surg.
25:35–40. 2002.
|
|
45
|
Patil V, Joshi A, Noronha V, Deodhar J,
Bhattacharjee A, Dhumal S, Chandrakanth MV, Karpe A, Talreja V,
ChandRasekharan A, et al: Expectations and preferences for
palliative chemotherapy in head and neck cancers patients. Oral
Oncol. 63:10–15. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xiao H, Zhang Q, Lin Y, Reddy BS and Yang
CS: Combination of atorvastatin and celecoxib synergistically
induces cell cycle arrest and apoptosis in colon cancer cells. Int
J Cancer. 122:2115–2124. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Goldstein JL and Brown MS: Regulation of
the mevalonate pathway. Nature. 343:425–430. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ogunwobi OO and Beales IL: Statins inhibit
proliferation and induce apoptosis in Barrett's esophageal
adenocarcinoma cells. Am J Gastroenterol. 103:825–837. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kundu N, Smyth MJ, Samsel L and Fulton AM:
Cyclooxygenase inhibitors block cell growth, increase ceramide and
inhibit cell cycle. Breast Cancer Res Treat. 76:57–64. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kim SH, Song SH, Kim SG, Chun KS, Lim SY,
Na HK, Kim JW, Surh YJ, Bang YJ and Song YS: Celecoxib induces
apoptosis in cervical cancer cells independent of cyclooxygenase
using NF-kappab as a possible target. J Cancer res Clin Oncol.
130:551–560. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Grösch S, Tegeder I, Niederberger E,
Bräutigam L and Geisslinger G: COX-2 independent induction of cell
cycle arrest and apoptosis in colon cancer cells by the selective
COX-2 inhibitor celecoxib. FASEB J. 15:2742–2744. 2001.PubMed/NCBI
|
|
52
|
Kardosh A, Blumenthal M, Wang WJ, Chen TC
and Schönthal AH: Differential effects of selective COX-2
inhibitors on cell cycle regulation and proliferation of
glioblastoma cell lines. Cancer Biol Ther. 3:55–62. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu JD, Wang YJ, Chen CH, Yu CF, Chen LC,
Lin JK, Liang YC, Lin SY and Ho YS: Molecular mechanisms of G0/G1
cell-cycle arrest and apoptosis induced by terfenadine in human
cancer cells. Mol Carcinog. 37:39–50. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Berishaj M, Gao SP, Ahmed S, Leslie K,
Al-Ahmadie H, Gerald WL, Bornmann W and Bromberg JF: Stat3 is
tyrosine-phosphorylated through the interleukin-6/glycoprotein
130/Janus kinase pathway in breast cancer. Breast Cancer Res.
9:R322007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bollrath J, Phesse TJ, von Burstin VA,
Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T,
Canli O, Schwitalla S, et al: gp130-mediated Stat3 activation in
enterocytes regulates cell survival and cell-cycle progression
during colitis-associated tumorigenesis. Cancer Cell. 15:91–102.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liu Y, Liu A, Li H, Li C and Lin J:
Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced
JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
Cancer Prev Res (Phila). 4:1296–1305. 2011. View Article : Google Scholar
|
|
57
|
Bianchi M, Broggini M, Balzarini P,
Franchi S and Sacerdote P: Effects of nimesulide on pain and on
synovial fluid concentrations of substance P, interleukin-6 and
interleukin-8 in patients with knee osteoarthritis: Comparison with
celecoxib. Int J Clin Pract. 61:1270–1277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yokota K, Miyazaki T, Hirano M, Akiyama Y
and Mimura T: Simvastatin inhibits production of interleukin 6
(IL-6) and IL-8 and cell proliferation induced by tumor necrosis
factor-alpha in fibroblast-like synoviocytes from patients with
rheumatoid arthritis. J Rheumatol. 33:463–471. 2006.PubMed/NCBI
|
|
59
|
Yuan A, Yang PC, Yu CJ, Chen WJ, Lin FY,
Kuo SH and Luh KT: Interleukin-8 messenger ribonucleic acid
expression correlates with tumor progression, tumor angiogenesis,
patient survival, and timing of relapse in non-small-cell lung
cancer. Am J respir Crit Care Med. 162:1957–1963. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Masuya D, Huang C, Liu D, Kameyama K,
Hayashi E, Yamauchi A, Kobayashi S, Haba R and Yokomise H: The
intratumoral expression of vascular endothelial growth factor and
interleukin-8 associated with angiogenesis in nonsmall cell lung
carcinoma patients. Cancer. 92:2628–2638. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wei D, Wang L, He Y, Xiong HQ, Abbruzzese
JL and Xie K: Celecoxib inhibits vascular endothelial growth factor
expression in and reduces angiogenesis and metastasis of human
pancreatic cancer via suppression of Sp1 transcription factor
activity. Cancer res. 64:2030–2038. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lee HC, Park IC, Park MJ, An S, Woo SH,
Jin HO, Chung HY, Lee SJ, Gwak HS, Hong YJ, et al: Sulindac and its
metabolites inhibit invasion of glioblastoma cells via
down-regulation of Akt/PKB and MMP-2. J Cell Biochem. 94:597–610.
2005. View Article : Google Scholar
|
|
63
|
Ostrowski J, Wocial T, Skurzak H and
Bartnik W: Do altering in ornithine decarboxylase activity and gene
expression contribute to antiproliferative properties of COX
inhibitors? Br J Cancer. 88:1143–1151. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Peluffo GD, Stillitani I, Rodríguez VA,
Diament MJ and Klein SM: Reduction of tumor progression and
paraneoplastic syndrome development in murine lung adenocarcinoma
by nonsteroidal antiinflammatory drugs. Int J Cancer. 110:825–830.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Björkhem-Bergman L, Lindh JD and Bergman
P: What is a relevant statin concentration in cell experiments
claiming pleiotropic effects? Br J Clin Pharmacol. 72:164–165.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Gauthaman K, Fong CY and Bongso A:
Statins, stem cells, and cancer. J Cell Biochem. 106:975–983. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Thelen KM, Rentsch KM, Gutteck U, Heverin
M, Olin M, Andersson U, von Eckardstein A, Björkhem I and Lütjohann
D: Brain cholesterol synthesis in mice is affected by high dose of
simvastatin but not of pravastatin. J Pharmacol Exp Ther.
316:1146–1152. 2006. View Article : Google Scholar
|
|
68
|
Lai GH, Zhang Z and Sirica AE: Celecoxib
acts in a cyclooxygenase-2-independent manner and in synergy with
emodin to suppress rat cholangiocarcinoma growth in vitro through a
mechanism involving enhanced Akt inactivation and increased
activation of caspases-9 and -3. Mol Cancer Ther. 2:265–271.
2003.PubMed/NCBI
|
|
69
|
Gauthaman K, Manasi N and Bongso A:
Statins inhibit the growth of variant human embryonic stem cells
and cancer cells in vitro but not normal human embryonic stem
cells. Br J Pharmacol. 157:962–973. 2009. View Article : Google Scholar : PubMed/NCBI
|
